ArticleCureus2026
Intravenous Immunoglobulin Induces Sustained Hemostatic Responses in IgM Paraprotein-Associated Acquired Von Willebrand Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired von Willebrand syndrome (AVWS) associated with monoclonal gammopathy is rare, and current evidence suggests that intravenous immunoglobulin (IVIG) is effective primarily in IgG-mediated disease, with limited benefit in IgM-associated cases. We describe a patient with life-threatening AVWS associated with IgM lambda monoclonal gammopathy secondary to lymphoplasmacytic lymphoma who demonstrated a sustained response to IVIG. A previously healthy woman developed severe mucocutaneous and gastrointestinal bleeding followed by intracranial hemorrhage despite treatment with desmopressin, von Willebrand factor (VWF) concentrates, and antifibrinolytic therapy. Diagnostic evaluation revealed reduced VWF antigen, VWF activity, and factor VIII levels, along with an IgM lambda paraprotein and biopsy-confirmed lymphoplasmacytic lymphoma with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.